Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 07 November 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) has released an extensive new final guidance document on the design of pivotal clinical investigations meant to support the approval of medical devices.
The 57-page guidance, Design Considerations for Pivotal Clinical Investigations for Medical Devices, was first released in draft form August 2011 and pertains to the stages of development in which a device is evaluated for safety and efficacy, otherwise known as the pivotal stage of development.
In general, such studies are used to support premarket approval applications (PMAs), but a smaller subset may also be used to support premarket notification [510(k)s] and de novo submissions as well.
As explained by FDA, the guidance elaborates on various "principles" of study design that will meet FDA's expectations for premarket clinical data requirements, but regulators stressed it is not meant as a "comprehensive tutorial on the best clinical and statistical practices for investigational medical device studies."
The guidance is divided into seven sections, with several containing extensive sub-sections:
Design Considerations for Pivotal Clinical Investigations for Medical Devices
Federal Register
Tags: De Novo, 510(k), PMA, guidance, clinical trials, medical device
Regulatory Focus newsletters
All the biggest regulatory news and happenings.